RxDoctor Payments Data

Sergio Garcia, MD

Internal Medicine · Miami, FLNPI 1548462740

Payments from drug & device makers

$6,559in general payments, 2019–2025

Across 17 payments — averaging $385.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • H. Lundbeck A S$6K
  • Boston Scientific$159
  • AstraZeneca$124
  • Metuchen Pharmaceuticals$119
  • Eisai Inc.$115
  • Jazz Pharmaceuticals Inc.$109
  • plus $353 from 7 others

What the payments were for

  • Food & beverage$86689%
  • Education$11211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
H. Lundbeck A S3$5,581
Boston Scientific1$159
AstraZeneca2$124
Metuchen Pharmaceuticals1$119
Eisai Inc.1$115
Jazz Pharmaceuticals Inc.1$109
Insmed, Inc.1$100
Novastep Inc.1$90
BD1$46
Medtronic1$42
AbbVie2$38
Pfizer1$23
Gilead1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,559 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,253
Medicare patients
136
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$195,497
EliquisApixaban82$83,115
TradjentaLinagliptin67$78,205
ProliaDenosumab36$61,107
JardianceEmpagliflozin38$41,069
MounjaroTirzepatide31$36,749
FarxigaDapagliflozin Propanediol33$33,939
JanuviaSitagliptin Phosphate28$30,207
EntrestoSacubitril/Valsartan21$21,967
XareltoRivaroxaban17$21,428
MyrbetriqMirabegron17$16,155
Tresiba Flextouch U-100Insulin Degludec25$14,802
VascepaIcosapent Ethyl15$13,112
SynthroidLevothyroxine Sodium124$12,865
LinzessLinaclotide13$8,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$83,11582 claims
AstraZenecaFarxiga$124$33,93933 claims
AbbVieSynthroid, Linzess$38$21,089137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →